19ME023 - Providers’ Clinical Support System: Buprenorphine Office-Based Treatment for Opioid Use Disorders, The “Half and Half” Course

Jun 27, 2019 Closed Medicine

19ME023 - Providers’ Clinical Support System: Buprenorphine Office-Based Treatment for Opioid Use Disorders, The “Half and Half” Course

Description

ONLINE REGISTRATION IS NOW CLOSED.
WALK-INS ARE WELCOME!




Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen, moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase is predominantly due to an alarming increase in addiction to prescription opioid analgesic medications. Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.

Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own-training that must be completed along with a post test). This training meets the requirements for physicians; however additional training is required for advanced practice providers. The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.

This program includes up to 2.0 hours of controlled substances content. Per NCAC rules: As of July 1, 2017, all physicians (other than residents), physician assistants, nurse practitioners, podiatrists, and dentists who prescribe controlled substances must satisfy the controlled-substance prescribing CE requirements as set forth by their licensing boards. Requirements vary by discipline and board.

MAHEC engages in evaluation activities to better understand the impact of our programs. By registering for this course, you agree that we may use your personal information in evaluative research regarding this program. Any reports published will be de-identified and reported in aggregate format.

Target Audience

The program is recommended for prescribers in primary care, emergency medicine, pain management, psychiatric, HIV, and addiction medicine. (Not a prescriber? CLICK HERE)

Objectives

  • Review addiction treatment in office-based practices
  • Discuss the pharmacological treatments of opioid use disorder
  • Determine what medical record documentation must be followed
  • Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
  • Describe how to take a patient history and evaluation
  • Review safety concerns and drug interactions

Faculty

  • Blake Fagan, MD
  • Shuchin Shukla, MD, MPH

Fees

Brochure / Registration Form